Egide voted to survive, and handed the board the right to dilute it

On paper the annual meeting of Egide, a French maker of hermetically sealed packages for the electronics inside night-vision and missile systems, was unremarkable. On September 10th its shareholders approved the 2025 accounts, ratified a co-opted director and declined one obscure technical resolution, then went home. A shareholder who bothered to read the numbers would struggle to call the meeting routine. Egide's owners had just voted, by 99.9%, to keep a company alive whose equity has fallen to barely a third of its stated share capital — a threshold at which French law forces shareholders to choose between dissolution and survival — and, in the same breath, handed directors the machinery to dilute them.

The balance sheet explains the contortions. In 2025 Egide lost €3.11m on revenue of €31.3m, a worse net result than 2024's €2.37m loss. The loss pushed shareholders' equity down to €3.25m against share capital of €9.8m. When equity drops below half of capital, Article L.225-248 of the commercial code obliges the general meeting to decide whether the company should be wound up. Resolution 9, the continuation vote, passed at 99.86%; a separate resolution gave the board power to reduce capital by cancelling treasury shares, a bookkeeping step that lifts the equity-to-capital ratio towards the legal floor.

None of this need alarm a holder who trusts the turnaround story. Egide's two surviving factories, in Bollène, France, and Cambridge, Maryland, turned EBITDA-positive in 2025 for the first time in years; revenue is growing in the defence and aerospace niches the group has refocused on. The market capitalisation is a little under €17m, and one small-cap research house, GreenSome Finance, calls the shares a speculative buy with a €1.31 target. The trouble is not the operating story. It is the funding.

The meeting's real content was the authorisation it handed the board. Resolutions 10 through 17 approved capital increases with and without pre-emptive subscription rights — including private placements, which existing owners cannot block and which dilute them at the directors' discretion. Egide ended 2025 with €5.4m of net debt against just €1.98m of cash, and its €0.7m of EBITDA (roughly a 2% margin) is nowhere near enough to repair capital and pay down borrowings at once. The board now holds, in effect, a signed mandate to raise fresh money on its own terms. No raise has been announced; none needs to be, for the investor to price in the probability.

The single vote that did not go the board's way is oddly reassuring, and revealing. Resolution 18, which would have issued shares to employees through a savings plan, was rejected with 100% of votes against — a rare moment of unanimity, aimed squarely at visible dilution. Shareholders are evidently minded to defend their stake. Yet they accepted, at 93.5% or higher, the far larger dilution that a private placement represents. The pattern points to a rational-if-uncomfortable bargain: owners will tolerate new money on management's terms rather than force a liquidation that would return them nothing. Continuation, in this context, is not confidence. It is the least-bad option on a table where the alternative is worthlessness.

The governance machinery adds texture. Egide spent May 15th to July 8th on Euronext Growth's penalty bench, returning to normal trading after publishing its 2025 annual report on July 7th — a marker of reporting discipline that the recovery narrative would do well to outgrow. The structure of repeated, small rights issues, the last of which was only 92.5% subscribed in late 2024, hints at a shareholder base with a dwindling appetite to fund the journey on its own.

What, then, does the vote actually confer? Not rescue, but time. The defence-aerospace order book is real, and the decision to close the loss-making San Diego site removed a persistent drag, even if the transferred production does not fully contribute until 2027. But a business that cannot earn its own way to safety must pay for survival in shares, and the price of that payment is now formally on the board's terms. For a prospective buyer, the question is not whether Egide's niche is good — it is. It is whether the future returns accrue to today's 19.8m shares, or to the versions of them that a private placement will issue next. Wall Street is not wrong that the niche works. It is merely premature to assume the current shareholders will keep the whole of it.